Eating disorders (EDs) represent a major area of concern under GLP-1 treatment. Tirzepatide profoundly alters the relationship with food, which can improve some EDs but also reveal or worsen others. EDs and obesity: a frequent comorbidity Binge eating disorder affects 20 to 30% of … Read more
The guilt of taking medication for weight loss affects a majority of patients on GLP-1 agonists. This shame, fueled by moralizing discourses on obesity, is a major obstacle to well-being and treatment adherence. It’s time to deconstruct it. Why guilt is so widespread A survey by the World Obesity Federation … Read more
The links between Mounjaro and mental health are under close scrutiny. While tirzepatide is not an antidepressant, the weight loss and hormonal changes it induces can have significant effects on mood and psychological well-being. Tirzepatide and neurotransmitters: what research shows GLP-1 and GIP receptors are … Read more
Body image is often out of sync with physical reality in patients on GLP-1. The mirror reflects a transformed body, but the mind retains the perception of the former body. This phenomenon, well-documented in psychology, requires particular attention during treatment. The disconnect between real body and mental image. Tirzepatide can cause a … Read more
Rapid weight loss with Mounjaro isn’t just about physical transformation. The psychological impact is profound and often underestimated: identity upheaval, disconnect between body and mental image, and reactions from those around you. Understanding these mechanisms is essential for a smooth journey. The psychological paradox of rapid weight loss Weight loss … Read more
The 10,000-step myth has been debunked by science, but moving more remains essential when taking GLP-1 agonists. Discover evidence-based physical activity goals and how to integrate movement into your daily life with tirzepatide. The 10,000-step myth: commercial origin The figure of 10,000 steps … Read more
Pelvic floor strengthening is a rarely discussed but essential exercise for obese patients, especially during weight loss with GLP-1 agonists. Urinary incontinence affects 60% of obese women and 30% of men, and it significantly improves with perineal rehabilitation. The pelvic floor: an overlooked muscle in … Read more
Physical exercise can trigger or worsen nausea with Mounjaro. Understanding the mechanisms involved and adapting your workout allows you to maintain regular physical activity despite this frequent side effect of tirzepatide. Why exercise aggravates nausea with GLP-1 Physical exertion redistributes blood flow to the muscles at the expense of the digestive system, further slowing … Read more
HIIT and moderate cardio offer complementary approaches for patients on tirzepatide. Choosing the right type of cardiovascular training depends on your treatment phase, physical condition, and body composition goals. HIIT vs moderate cardio: definitions and differences. HIIT (High-Intensity Interval Training) alternates phases of intense effort … Read more
Resuming exercise after starting a GLP-1 treatment requires a progressive and adapted approach. Between fatigue, nausea, and risk of injury, discover the optimal schedule to reintroduce physical activity with tirzepatide. When to start exercising on GLP-1? The timing question is crucial. The first weeks of tirzepatide treatment are … Read more
Swimming and aqua aerobics offer unique benefits for patients on Mounjaro: joint-friendly exercise, natural water resistance, and mental well-being. Discover how to integrate these aquatic activities into your tirzepatide regimen. Why aquatic activities are ideal with GLP-1 For overweight or obese patients, land-based exercise can be … Read more
Sarcopenia is the most underestimated risk of GLP-1 agonist treatments. This muscle wasting, accelerated by the caloric deficit of tirzepatide, can compromise long-term mobility and metabolism if not actively prevented. What is sarcopenia and why is it exacerbated under GLP-1? Sarcopenia refers to the loss … Read more